Contact SCGE




Clinical Trial Report

Gene Therapy Trial Report

Summary

Safety and Efficacy Study of Novel Gene Therapy ZM-02 for Retinitis Pigmentosa Patients


NCTID NCT06292650 (View at clinicaltrials.gov)
Description
Development Status Active
Indication Retinitis Pigmentosa
Disease Ontology Term DOID:10584
Compound Name ZM-02
Compound Description rAAV-PsCatCh2.0
Sponsor Zhongmou Therapeutics
Funder Type Industry
Recruitment Status
Recruiting
Enrollment Count 12
Results Posted Not Available

Therapy Information


Target Gene/Variant Ch2.0
Therapy Type Gene transfer
Therapy Route In-vivo
Mechanism of Action Overexpression of protective allele/gene
Route of Administration Intravitreal
Drug Product Type Viral vector
Target Tissue/Cell
Delivery System Viral transduction
Vector Type AAV
Editor Type
Dose 1 Undisclosed low dose
Dose 2 Undisclosed high dose
Dose 3
Dose 4
Dose 5

Study Record Dates


Current Stage Early phase1
Submit Date 2024-02-27
Completion Date 2028-12-25
Last Update 2024-12-13

Participation Criteria


Eligible Age 18 Years - 65 Years
Standard Ages Adult, Older adult
Sexes Eligible for Study ALL

Locations


No.of Trial Sites 1
Locations China

Regulatory Information


Has US IND False
FDA Designations Orphan Drug Designation
Recent Updates Two patients treated early 2024

Resources/Links